comparemela.com

Latest Breaking News On - சிந்தியுங்கள் முதலீடுகள் - Page 15 : comparemela.com

PharmEasy gets $300 million booster shot for Thyrocare deal

ETtech Exclusive: PharmEasy gets $300 million booster shot for Thyrocare deal SECTIONS Last Updated: Jun 28, 2021, 08:08 AM IST Share Synopsis PharmEasy has raised $300 million more, bringing the total funding received by the online pharmacy since April to $650 million, most of which will be used to fund its ongoing acquisition of diagnostics chain Thyrocare. ETtech The Pharmeasy-Thyrocare deal will allow the online pharmacy to offer four key elements of healthcare information, consult, test and treatment at a time when online adoption is growing due to the pandemic. (Illustration: Rahul Awasthi/ETtech) Bengaluru:PharmEasy has raised $300 million more, led by its existing investors, bringing the total funding received by the online pharmacy since April to $650 million, most of which will be used to fund its ongoing acquisition of diagnostic chain Thyrocare, a top executive told ET.

India-related SPAC raises $170mn on Nasdaq

India-related SPAC raises $170mn on Nasdaq Top Searches India-related SPAC raises $170mn on Nasdaq TNN / Jun 15, 2021, 05:49 IST FacebookTwitterLinkedinEMail BENGALURU: Private equity veteran Rohan Ajila and Manipal Technologies chairman Gautham Pai’s consumer sector focused SPAC (special purpose acquisition company) has raised $170 million in an IPO in the US. This probably marks the first fund raise by an India-related SPAC. The SPAC, called Global Consumer Acquisition Corp (GCAC), is listed on Nasdaq. SPACs, also known as blank-cheque companies, are shell companies that launch IPOs with a promise to invest in or acquire a company within a set timeline – normally18 to 24 months. SPACs have become extremely popular among investment firms and startups over the past two years.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.